DR. DAVID LAWRENCE CHAMBERLAND MD NPI 1447293311

NPI Details

DR. David Lawrence Chamberland, MD is a rheumatology internal medicine in Medford, OR with 25 years of experience. The provider is an internist who treats diseases of joints, muscle, bones and tendons. This specialist diagnoses and treats arthritis, back pain, muscle strains, common athletic injuries and collagen diseases. DR. David Lawrence Chamberland, MD NPI is 1447293311. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: OREGON HEALTH SCIENCES UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:2001

The provider's business location address is:

1365 POPLAR DR
MEDFORD, OR
ZIP 97504-207
Phone: (541) 773-2233

The NPI 1447293311 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, tocilizumab, 1 mg (HCPCS:J3262)
• Injection, golimumab, 1 mg, for intravenous use (HCPCS:J1602)
• Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0717)
• Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0129)
• Injection, infliximab-abda, biosimilar, (renflexis), 10 mg (HCPCS:Q5104)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg (HCPCS:J7325)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Red blood cell sedimentation rate, to detect inflammation, automated (HCPCS:85652)
• Measurement c-reactive protein for detection of infection or inflammation (HCPCS:86140)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, triamcinolone acetonide, not otherwise specified, 10 mg (HCPCS:J3301)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Measurement of complement (immune system proteins), antigen, (HCPCS:86160)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Measurement of antibody for assessment of autoimmune disorder, any method (HCPCS:86235)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Aspiration and/or injection of fluid from large joint (HCPCS:20610)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• X-ray of hand, 2 views (HCPCS:73120)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Rheumatoid factor analysis (HCPCS:86430)
• Creatine kinase (cardiac enzyme) level, total (HCPCS:82550)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Screening test for autoimmune disorder (HCPCS:86038)
• Automated urinalysis test (HCPCS:81003)
• X-ray of knee, 1-2 views (HCPCS:73560)
• Measurement of antibody for rheumatoid arthritis assessment (HCPCS:86200)
• Measurement of dna antibody, native or double stranded (HCPCS:86225)
• X-ray of foot, 2 views (HCPCS:73620)
• X-ray of shoulder, minimum of 2 views (HCPCS:73030)
• Uric acid level, blood (HCPCS:84550)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Microsomal antibodies (autoantibody) measurement (HCPCS:86376)
• Injection of drug or substance into vein (HCPCS:96374)
• X-ray of lower and sacral spine, 2-3 views (HCPCS:72100)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Glutamyltransferase (liver enzyme) level (HCPCS:82977)
• Crystal identification from tissue or body fluid (HCPCS:89060)
• X-ray of joint between lower spine and hip bone, 3 or more views (HCPCS:72202)
• Testing for presence of drug, read by direct observation (HCPCS:80305)
• X-ray of wrist, 2 views (HCPCS:73100)
• Aspiration and/or injection of fluid from small joint (HCPCS:20600)
• Influenza vaccine, quadrivalent, 0.5 ml dosage (HCPCS:90688)

The enumeration date for this NPI number is 6/14/2006 and was last updated on 11/20/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: